Artiva Biotherapeutics (ARTV) Liabilities and Shareholders Equity (2023 - 2026)

Artiva Biotherapeutics (ARTV) has 4 years of Liabilities and Shareholders Equity data on file, last reported at $106.0 million in Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $106.0 million, down 44.6% year-over-year; the trailing twelve-month figure through Mar 2026 was $555.1 million (down 20.96% YoY), and the FY2025 annual result was $130.9 million, down 37.52% from the prior year.
• Liabilities and Shareholders Equity eased to $106.0 million in Q1 2026 per ARTV's latest filing, from $130.9 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $225.6 million in Q3 2024 and troughed at $75.9 million in Q2 2024.
• A 4-year average of $151.4 million and a median of $148.9 million in 2025 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2025 and 2026: Liabilities and Shareholders Equity jumped 123.14% in 2025, then slumped 44.6% in 2026.
• A 4-year view of Liabilities and Shareholders Equity shows it stood at $105.1 million in 2023, then soared by 99.38% to $209.6 million in 2024, then plunged by 37.52% to $130.9 million in 2025, then retreated by 19.08% to $106.0 million in 2026.
• Business Quant data shows ARTV's Liabilities and Shareholders Equity at $106.0 million in Q1 2026, $130.9 million in Q4 2025, and $148.9 million in Q3 2025.